PNC FINANCIAL SERVICES GROUP, INC. - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.

Quarter-by-quarter ownership
PNC FINANCIAL SERVICES GROUP, INC. ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,942
-86.5%
916
-69.6%
0.00%
Q2 2023$14,356
+1674.5%
3,016
+2023.9%
0.00%
Q1 2023$809
-99.0%
142
-98.3%
0.00%
Q4 2022$83,314
-60.5%
8,257
-12.1%
0.00%
Q3 2022$211,000
-17.9%
9,397
-9.2%
0.00%
Q2 2022$257,000
-1.2%
10,345
+53.6%
0.00%
Q1 2022$260,000
-22.6%
6,737
+17.1%
0.00%
Q4 2021$336,000
+40.0%
5,751
+42.0%
0.00%
Q3 2021$240,000
-31.6%
4,051
+0.4%
0.00%
Q2 2021$351,000
+31.5%
4,033
+24.7%
0.00%
Q1 2021$267,000
+56.1%
3,233
+72.9%
0.00%
Q4 2020$171,000
-20.8%
1,870
-65.6%
0.00%
Q3 2020$216,000
+16.1%
5,4300.0%0.00%
Q2 2020$186,000
+45.3%
5,430
-6.4%
0.00%
Q1 2020$128,000
-26.4%
5,800
-34.7%
0.00%
Q4 2019$174,000
-1.1%
8,880
-22.0%
0.00%
Q3 2019$176,000
-20.0%
11,380
+4.8%
0.00%
Q2 2019$220,000
+15.8%
10,8600.0%0.00%
Q1 2019$190,000
+8.0%
10,860
-20.4%
0.00%
Q4 2018$176,000
+15.8%
13,640
+45.4%
0.00%
Q3 2018$152,000
+26.7%
9,380
-10.8%
0.00%
Q2 2018$120,000
+1100.0%
10,520
+952.0%
0.00%
Q1 2014$10,000
+66.7%
1,0000.0%0.00%
Q4 2013$6,0001,0000.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 716,392$11,126,00012.18%
Polaris Venture Management Co. V, L.L.C. 1,139,783$17,701,00010.06%
Grosvenor Holdings, L.L.C. 2,285,714$35,497,0006.41%
Redmile Group, LLC 11,216,809$174,197,0005.83%
Casdin Capital, LLC 2,550,000$39,601,500,0004.10%
DAFNA Capital Management LLC 470,000$7,299,0002.74%
Ghost Tree Capital, LLC 350,000$5,436,0001.38%
Artal Group S.A. 2,000,000$31,060,0001.24%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 1,952,897$30,328,0001.24%
Copernicus Capital Management, LLC 75,000$1,165,0001.08%
View complete list of FATE THERAPEUTICS INC shareholders